Vertex to acquire Crinetics in $10 billion deal, expanding rare endocrine disorder pipeline

Vertex announced on July 7, 2026 that it will acquire Crinetics Pharmaceuticals for $10 billion, marking the company’s largest-ever transaction.

Crinetics is a biotech focused on developing treatments for rare endocrine disorders, a therapeutic area that complements Vertex’s existing portfolio.

The acquisition is expected to broaden Vertex’s pipeline and strengthen its position in the rare‑disease market, a move that investors and industry observers are watching closely.